Back

The impact of modifiable risk factors on readmissions during the vulnerable period in patients with heart failure

13 May 2024 (09:00 - 10:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 5 Lifestyle Modification HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Andreea-Elena Lacraru

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

5 More presentations in this session

Presentation thumbnail
AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study
Professor M. Ufnal (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Effect of intravenous FCM therapy on myocardial work indices in patients with HFrEF and ID.
Professor A. Safarova (Baku, AZ)
Abstract Slides Video
Presentation thumbnail
Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance
Professor J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
ARNi treatment in adults with Tetralogy of Fallot: a single-centre experience
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Effect of guideline-recommended medical therapy according to blood urea nitrogen
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

13 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Heart failure hospitalization and mapping of post-discharge care: insights from a slovakian cohort study
thumbnail
Congress Presentation
Demographic characteristics and clinical outcomes in HFrEF patients treated at a specialized outpatient clinic in a tertiary center
thumbnail
Congress Presentation
Mathematical model for estimating readmissions during the vulnerable period of patients with heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources